[Lab] split one vial across VendorInvestigate and PeptideMeter — 98.6% and 93.7%
split one vial across VendorInvestigate and PeptideMeter — 98.6% and 93.7%. I will put the method line and the batch identifier up front because that is what makes this checkable.
Hard numbers: 98.6% and 93.7%. Anything softer than that is flagged as an impression.
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.
Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.
Not convinced. You are attributing a week of injection-site soreness to the glucagon arm when the escalation rate alone would explain it.
Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.
Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.
a lot of the confident posting here is extrapolation
Yes — the comparison threads are apples to oranges and they generate more heat than anything else here.
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
the phase 2 numbers were striking and they were also 48 weeks in a small population
Kept a log specifically because there is so little published. It is one person and it is not data.
nothing here is available as a prescription product, so read every thread with that in mind
dose escalation in the trials was slow for a reason
- 1Nothing containing this compound is approved anywhere. Research-use-only…7 comments in this branch · started by u/marit_laurent